Uro-Vaxom

Hauptinformation

  • Handelsname:
  • Uro-Vaxom Kapseln
  • Darreichungsform:
  • Kapseln
  • Zusammensetzung:
  • lysatum bacteriorum lyophilisatum Endwerte. escherichia coli viva 6 mg, natrii hydrogenoglutamas anhydricus, antiox.: E 310, excipiens für die Kapsel.
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • allopathic Droge

Dokumenten

Lokalisierung

  • Erhältlich in:
  • Uro-Vaxom Kapseln
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Bakterien- und Hefepräparate
  • Therapiebereich:
  • immuno-stimulierende wirkung bei infektionen der harnwege

Weitere Informationen

Status

  • Quelle:
  • Swissmedic - Swiss Agency for Therapeutic Products
  • Zulassungsnummer:
  • 598
  • Berechtigungsdatum:
  • 19-03-1998
  • Letzte Änderung:
  • 23-01-2018

Packungsbeilage: zusammensetzung, kinische angaben, nebenwirkungen, wechselwirkungen, dosierung, schwangerschaft, stillzeit

Patienteninformation

Uro-Vaxom®

OM Pharma SA

Was ist Uro-Vaxom und wann wird es angewendet?

Auf Verschreibung des Arztes oder der Ärztin.

Uro-Vaxom ist ein biologisches Arzneimittel und wird zur Anregung des Immunsystems

angewendet, um die natürlichen Abwehrkräfte zu stärken. Uro-Vaxom kann wiederkehrende

Infektionen der Harnwege, insbesondere Blasenentzündungen, vorbeugen. Es kann auch zusammen

mit anderen Medikamenten, die eventuell während der akuten Phase der Harnwegsinfektionen

verschrieben wurden, angewendet werden.

Was sollte dazu beachtet werden?

Falls Ihnen Ihr Arzt gleichzeitig auch Antibiotika oder Mittel zur Desinfektion der Harnwege

verschrieben hat, müssen Sie diese ebenfalls einnehmen.

Wann darf Uro-Vaxom nicht angewendet werden?

Wenn Sie allergisch gegen lyophilisierte Bakterienlysate von Escherichia coli oder einen der im

Abschnitt «Was ist in Uro-Vaxom enthalten?» aufgeführten Bestandteile dieses Arzneimittels sind.

Wann ist bei der Einnahme/Anwendung von Uro-Vaxom Vorsicht geboten?

Brechen Sie bei Hautreaktionen, Fieber oder lokalisierten Schwellungen (Ödemen) die Behandlung

ab und informieren Sie Ihren Arzt oder Ihre Ärztin, da es sich um allergische Reaktionen handeln

kann.

Informieren Sie Ihren Arzt, falls Sie Immunsuppressiva einnehmen. Dies sind Arzneimittel, die zur

Verringerung von Immunreaktionen des Körpers (zum Beispiel nach einer Organtransplantation)

eingesetzt werden. Sie können die Wirkung der Behandlung mit Uro-Vaxom verringern oder

hemmen.

Die Verabreichung von Uro-Vaxom bei Kindern unter 4 Jahren wird nicht empfohlen.

Bisher liegen keine Hinweise vor, dass die Verkehrstüchtigkeit und das Bedienen von Maschinen

durch die Anwendung von Uro-Vaxom beeinträchtigt wird.

Informieren Sie Ihren Arzt oder Apotheker bzw. Ihre Ärztin oder Apothekerin, wenn Sie

·an anderen Krankheiten leiden,

·Allergien haben,

·andere Arzneimittel (auch selbst gekaufte!) einnehmen.

Darf Uro-Vaxom während einer Schwangerschaft oder in der Stillzeit eingenommen/angewendet

werden?

Informieren Sie Ihren Arzt bzw. Ihre Ärztin, wenn Sie schwanger sind oder es werden möchten.

Schwangerschaft

Während der Schwangerschaft sollten Sie die Anwendung von Uro-Vaxom vermeiden (vor allem

während des ersten Trimesters).

Stillzeit

Sie dürfen Uro-Vaxom während der Stillzeit nicht anwenden, ohne vorher Ihren Arzt um Rat zu

fragen.

Wie verwenden Sie Uro-Vaxom?

Präventive und/oder konsolidierende Behandlung

1 Kapsel täglich, vorzugsweise am Morgen auf nüchternen Magen einnehmen, während 3

aufeinander folgenden Monaten.

Behandlung von akuten Episoden: 1 Kapsel täglich, vorzugsweise am Morgen auf nüchternen Magen

einnehmen, bis zum Verschwinden der Symptome, jedoch mindestens während 10 aufeinander

folgenden Tagen.

Die Anwendung und Sicherheit von Uro-Vaxom bei Kindern unter 4 Jahren ist bisher nicht geprüft

worden. Ändern Sie nicht von sich aus die verschriebene Dosierung. Wenn Sie glauben, das

Arzneimittel wirke zu schwach oder zu stark, so sprechen Sie mit Ihrem Arzt oder Apotheker bzw.

mit Ihrer Ärztin oder Apothekerin.

Welche Nebenwirkungen kann Uro-Vaxom haben?

Uro-Vaxom kann unerwünschte Nebenwirkungen hervorrufen:

Häufig (kann bis zu 1 von 10 Personen betreffen)

Durchfall, Übelkeit, Kopfschmerzen, Verdauungsbeschwerden, Magenunverträglichkeit

Gelegentlich (kann bis zu 1 von 100 Personen betreffen)

Allergische Reaktionen, Bauchschmerzen, Hautausschlag, Juckreiz, Fieber

Sehr selten (betrifft weniger als eine von 10'000 Personen)

Schwellung (Ödem) des Mundes, Schwellung der Knöchel, Füsse oder Finger, Haarausfall

Wenn Sie Nebenwirkungen bemerken, die hier nicht beschrieben sind, sollten Sie Ihren Arzt oder

Apotheker bzw. Ihre Ärztin oder Apothekerin informieren.

Was ist ferner zu beachten?

Uro-Vaxom ist an einem trockenen Ort ausser Reichweite von Kindern aufzubewahren. Das

Arzneimittel darf nur bis zu dem auf dem Behälter mit «EXP» bezeichneten Datum verwendet

werden.

Bei Raumtemperatur (15 bis 25 °C) in der Originalverpackung lagern.

Weitere Auskünfte erteilt Ihnen Ihr Arzt oder Apotheker bzw. Ihre Ärztin oder Apothekerin. Diese

Personen verfügen über die ausführliche Fachinformation.

Was ist in Uro-Vaxom enthalten?

1 Kapsel Uro-Vaxom enthält 6 mg eines lyophilisierte Bakterienlysate von Escherichia coli sowie

Natriumglutamat und ein Antioxidans: Propylgallat (E 310).

Die sonstigen Bestandteile sind: Stärke (prägelatiniert), Magnesiumstearat, Mannitol;

Zusammensetzung der Kapselhülle: Gelatine, Eisenoxid gelb (E 172), Eisenoxid rot (E 172),

Titandioxid.

Zulassungsnummer

00598 (Swissmedic).

Wo erhalten Sie Uro-Vaxom? Welche Packungen sind erhältlich?

In Apotheken nur gegen ärztliche Verschreibung.

Packungen mit 30 und 90 Kapseln.

Zulassungsinhaberin

OM Pharma SA, Rue du Bois du Lan 22, 1217 Meyrin, Schweiz.

Diese Packungsbeilage wurde im Dezember 2014 letztmals durch die Arzneimittelbehörde

(Swissmedic) geprüft.

21-12-2018

Avian influenza overview August – November 2018

Avian influenza overview August – November 2018

Published on: Thu, 20 Dec 2018 Between 16 August and 15 November 2018, 14 highly pathogenic avian influenza (HPAI) A(H5N8) outbreaks in poultry establishments in Bulgaria and seven HPAI A(H5N6) outbreaks, one in captive birds in Germany and six in wild birds in Denmark and the Netherlands were reported in the European Union (EU). No human infection due to HPAI A(H5N8) and A(H5N6) viruses have been reported in Europe so far. Seroconversion of people exposed during outbreaks in Russia has been reported in...

Europe - EFSA - European Food Safety Authority EFSA Journal

19-12-2018

Wegmans Issues Voluntary Recall of Fresh Cauliflower Rice, Veggie/Cauliflower Rice Blend and Stir-Fry Mix with Cauliflower

Wegmans Issues Voluntary Recall of Fresh Cauliflower Rice, Veggie/Cauliflower Rice Blend and Stir-Fry Mix with Cauliflower

Rochester, NY – Wegmans Food Markets, Inc. has issued a voluntary recall of fresh Cauliflower Rice, Veggie Cauliflower Rice Blend and Stir-Fry Mix with Cauliflower, sold in the produce department between 12/7/18 and 12/18/18, because it may be contaminated with Escherichia coli O157:H7 bacteria (E. Coli O157:H7). E. coli O157:H7 causes a diarrheal illness often with bloody stools. Although most healthy adults can recover completely within a week, some people can develop a form of kidney failure called He...

FDA - U.S. Food and Drug Administration

18-12-2018

Adam Bros. Farming, Inc. Recalls Red and Green Leaf Lettuce and Cauliflower Because of Possible Health Risk

Adam Bros. Farming, Inc. Recalls Red and Green Leaf Lettuce and Cauliflower Because of Possible Health Risk

Adam Bros. Farming, Inc. of Santa Maria, California is recalling red leaf lettuce, green leaf lettuce and cauliflower harvested on November 27 through 30, 2018 out of an abundance of caution, because it may be contaminated with Escherichia coli O157:H7 bacteria (E. Coli O157:H7).

FDA - U.S. Food and Drug Administration

16-12-2018

Spokane Produce Voluntarily Recalls Northwest Cuisine Creations and Fresh&Local Sandwiches and Green Leaf Lettuce Filets

Spokane Produce Voluntarily Recalls Northwest Cuisine Creations and Fresh&Local Sandwiches and Green Leaf Lettuce Filets

Spokane Produce Inc. of Spokane, WA initiates a voluntary recall of sandwiches containing green leaf lettuce and foodservice lettuce filets following notice of a produce industry ingredient recall by Adam Bros. Farming Inc. Sandwich products bearing the Northwest Cuisine Creations and Fresh&Local labels. These prod- ucts are recalled because they may be contaminated with Escherichia coli O157:H7 bacteria (E. Coli O157:H7). E. coli O157:H7 causes a diarrheal illness often with bloody stools. Although most...

FDA - U.S. Food and Drug Administration

13-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D. and FDA Deputy Commissioner Frank Yiannas on new findings and updated consumer recommendations related to the romaine lettuce <i>E. coli</i> O157:H7 outbreak investigation

Statement from FDA Commissioner Scott Gottlieb, M.D. and FDA Deputy Commissioner Frank Yiannas on new findings and updated consumer recommendations related to the romaine lettuce <i>E. coli</i> O157:H7 outbreak investigation

Statement from FDA Commissioner Scott Gottlieb, M.D. and FDA Deputy Commissioner Frank Yiannas on new findings and updated consumer recommendations related to the romaine lettuce E. coli O157:H7 outbreak investigation

FDA - U.S. Food and Drug Administration

13-12-2018

The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017

The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017

Published on: Wed, 12 Dec 2018 This report of the European Food Safety Authority and the European Centre for Disease Prevention and Control presents the results of zoonoses monitoring activities carried out in 2017 in 37 European countries (28 Member States (MS) and nine non-MS). Campylobacteriosis was the commonest reported zoonosis and its EU trend for confirmed human cases increasing since 2008 stabilised during 2013–2017. The decreasing EU trend for confirmed human salmonellosis cases since 2008 end...

Europe - EFSA - European Food Safety Authority Publications

5-12-2018

Public health risks associated with food‐borne parasites

Public health risks associated with food‐borne parasites

Published on: Tue, 04 Dec 2018 Parasites are important food‐borne pathogens. Their complex lifecycles, varied transmission routes, and prolonged periods between infection and symptoms mean that the public health burden and relative importance of different transmission routes are often difficult to assess. Furthermore, there are challenges in detection and diagnostics, and variations in reporting. A Europe‐focused ranking exercise, using multicriteria decision analysis, identified potentially food‐borne ...

Europe - EFSA - European Food Safety Authority Publications

27-11-2018

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

Published on: Mon, 26 Nov 2018 Abstract In response to the EFSA call New approaches in identifying and characterizing microbial and chemical hazards, the project INNUENDO (https://sites.google.com/site/theinnuendoproject/) aimed to design an analytical platform and standard procedures for the use of whole‐genome sequencing in surveillance and outbreak investigation of food‐borne pathogens. The project firstly attempted to identify existing flaws and needs, and then to provide applicable cross‐sectorial ...

Europe - EFSA - European Food Safety Authority Publications

27-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on the current romaine lettuce <i>E. coli</i> O157:H7 outbreak investigation

Statement from FDA Commissioner Scott Gottlieb, M.D., on the current romaine lettuce <i>E. coli</i> O157:H7 outbreak investigation

Statement from FDA Commissioner Scott Gottlieb, M.D., on the current romaine lettuce E. coli O157:H7 outbreak investigation

FDA - U.S. Food and Drug Administration

17-11-2018

Evaluation of confirmatory data following the Article 12 MRL review for picolinafen

Evaluation of confirmatory data following the Article 12 MRL review for picolinafen

Published on: Fri, 16 Nov 2018 The applicant BASF Agro B.V. submitted a request to the competent national authority in Germany to evaluate the confirmatory data that were identified for picolinafen in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, a new validated analytical method for enforcement of the residue in dry/high starch‐, high water content‐, high acid content‐ and high oil content commodities ...

Europe - EFSA - European Food Safety Authority Publications

16-11-2018

FDA approves new drug to treat travelers’ diarrhea

FDA approves new drug to treat travelers’ diarrhea

FDA approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers’ diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.

FDA - U.S. Food and Drug Administration

1-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on findings from the romaine lettuce E. coli O157:H7 outbreak investigation and FDA’s efforts to prevent future outbreaks

Statement from FDA Commissioner Scott Gottlieb, M.D., on findings from the romaine lettuce E. coli O157:H7 outbreak investigation and FDA’s efforts to prevent future outbreaks

Statement from FDA Commissioner Scott Gottlieb, M.D., on findings from the romaine lettuce E. coli O157:H7 outbreak investigation and FDA’s efforts to prevent future outbreaks

FDA - U.S. Food and Drug Administration

26-10-2018

Safety and efficacy of l‐threonine produced by fermentation using Escherichia coli CGMCC 7.232 for all animal species

Safety and efficacy of l‐threonine produced by fermentation using Escherichia coli CGMCC 7.232 for all animal species

Published on: Thu, 25 Oct 2018 00:00:00 +0200 The product subject of this assessment is l‐threonine produced by fermentation with a genetically modified strain of Escherichia coli (CGMCC 7.232). It is intended to be used in feed and water for drinking for all animal species and categories. The production strain and its recombinant DNA were not detected in the additive. The product l‐threonine, manufactured by fermentation with E. coli CGMCC 7.232, does not raise any safety concern with regard to the gen...

Europe - EFSA - European Food Safety Authority Publications

28-9-2018

Avian influenza overview May – August 2018

Avian influenza overview May – August 2018

Published on: Thu, 27 Sep 2018 00:00:00 +0200 Between 16 May and 15 August 2018, three highly pathogenic avian influenza (HPAI) A(H5N8) outbreaks in poultry establishments and three HPAI A(H5N6) outbreaks in wild birds were reported in Europe. Three low pathogenic avian influenza (LPAI) outbreaks were reported in three Member States. Few HPAI and LPAI bird cases have been detected in this period of the year, in accordance with the seasonal expected pattern of LPAI and HPAI. There is no evidence to date ...

Europe - EFSA - European Food Safety Authority Publications

27-9-2018

Mauna Loa Macadamia Nut Corporation Voluntarily Recalls

Mauna Loa Macadamia Nut Corporation Voluntarily Recalls

Mauna Loa Macadamia Nut Corporation is voluntarily recalling all of its products produced at the Keaau facility between Sept. 6 - 21, 2018 due to a potential contamination of Escherichia coli (E. coli). The recall was initiated due to E. coli being detected in the well water and distribution system that supplies the firm's operations. No illnesses related to the water have been reported to the state.

FDA - U.S. Food and Drug Administration

11-9-2018

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Published on: Tue, 28 Aug 2018 00:00:00 +0200 Novel foods could represent a sustainable alternative to traditional farming and conventional foodstuffs. Starting in 2018, Regulation (EU) 2283/2015 entered into force, laying down provisions for the approval of novel foods in Europe, including insects. This Approved Regulation establishes the requirements that enable Food Business Operators to bring new foods into the EU market, while ensuring high levels of food safety for European consumers. The present ...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Modelling of inactivation through heating for quantitative microbiological risk assessment (QMRA)

Modelling of inactivation through heating for quantitative microbiological risk assessment (QMRA)

Published on: Mon, 27 Aug 2018 00:00:00 +0200 EFSA regards the household as a stage in the food chain that is important for the final number of food‐borne infections. The fate of a pathogen in the private kitchen largely depends on consumer hygiene during preparation of food and on its proper cooking, especially in the case of meat. Unfortunately, detailed information on the microbiological survival in meat products after heating in the consumer kitchen is lacking. The aim of the study was to improve th...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Scientific Opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) effect models for regulatory risk assessment of pesticides for aquatic organisms

Scientific Opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) effect models for regulatory risk assessment of pesticides for aquatic organisms

Published on: Thu, 23 Aug 2018 00:00:00 +0200 Following a request from EFSA, the Panel on Plant Protection Products and their Residues (PPR) developed an opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) models and their use in prospective environmental risk assessment (ERA) for pesticides and aquatic organisms. TKTD models are species‐ and compound‐specific and can be used to predict (sub)lethal effects of pesticides under untested (time‐variable) exposure conditions. Three differen...

Europe - EFSA - European Food Safety Authority Publications

30-5-2018

FDA approves new treatment for moderately to severely active ulcerative colitis

FDA approves new treatment for moderately to severely active ulcerative colitis

FDA today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis.

FDA - U.S. Food and Drug Administration

18-5-2018

MBI Distributing, Inc. Issues Voluntary Nationwide Recall of Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir Due to a Lack of Process Controls

MBI Distributing, Inc. Issues Voluntary Nationwide Recall of Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir Due to a Lack of Process Controls

MBI Distributing, Inc. is voluntarily recalling all lots of homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir, within expiry, to the consumer level. The drug products have been found to be manufactured with a lack of adequate controls.

FDA - U.S. Food and Drug Administration

18-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Cell-free solution of lysed Escherichia coli culture, strain Laves, decision type: , therapeutic area: , PIP number: P/0328/2018

Opinion/decision on a Paediatric investigation plan (PIP): Cell-free solution of lysed Escherichia coli culture, strain Laves, decision type: , therapeutic area: , PIP number: P/0328/2018

Opinion/decision on a Paediatric investigation plan (PIP): Cell-free solution of lysed Escherichia coli culture, strain Laves, decision type: , therapeutic area: , PIP number: P/0328/2018

Europe - EMA - European Medicines Agency

11-7-2018

Coliprotec F4/F18 (Prevtec Microbia GmbH)

Coliprotec F4/F18 (Prevtec Microbia GmbH)

Coliprotec F4/F18 (Active substance: Porcine post-weaning diarrhoea vaccine (live)) - Centralised - Yearly update - Commission Decision (2018)4522 of Wed, 11 Jul 2018

Europe -DG Health and Food Safety